Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXP003
- Development stage
- Unknown
- Lead developer
- Nuformix
- Modality
- Small Molecules
01
Overview
NXP003 is a small molecule therapeutic candidate developed by Nuformix, utilizing their proprietary cocrystal technology to create a novel crystalline form of an existing immuno-oncology drug. The program was designed to improve the physical and pharmacological properties of the lead molecule. NXP003 was featured in Nuformix's development pipeline around 2017, where it was described as being in Phase 1 development for immuno-oncology indications. However, the asset is no longer listed in the company's active pipeline as of recent updates, suggesting that development has been discontinued or the program has been deprioritized in favor of other assets like NXP002 and NXP004.
Beyond the preview
Go deeper on NXP003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXP003.